<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727074</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-19-01</org_study_id>
    <nct_id>NCT03727074</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream, With Efudex® (5-FU) Cream, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative efficacy and safety and of 5-FU Cream to the marketed formulation
      Efudex® (5-FU) Cream, and to demonstrate the superior efficacy of the two active formulations
      over that of the Vehicle Control Cream, in the treatment of actinic keratosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the safety and efficacy profiles of 5-FU Cream with Efudex® (5-FU) Cream, and to
      demonstrate the superior efficacy of the two active formulations over that of the Vehicle
      Control Cream, in the treatment of actinic keratosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment success</measure>
    <time_frame>week 6</time_frame>
    <description>Proportion of subjects, in the Per-Protocol (PP) population, with treatment success, defined as complete clearing (100% clearance of all AK lesions within the designated treatment area) at the End of Study visit</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Actinic Keratosis (AK)</condition>
  <arm_group>
    <arm_group_label>5-FU Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efudex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU Cream</intervention_name>
    <description>topical cream twice a day</description>
    <arm_group_label>5-FU Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efudex®</intervention_name>
    <description>topical cream twice a day</description>
    <arm_group_label>Efudex®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>topical cream twice a day</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female 18 years of age and older.

          2. Subject is able to understand and willing to sign Institutional Review Board (IRB)
             approved written informed consent for this study.

          3. Subject must be generally healthy, based on medical records, and free from any
             clinically significant disease, other than AK, that in the opinion of the investigator
             might interfere with the study evaluations.

          4. At least five (5) and no more than ten (10) clinically typical, visible or palpable,
             discrete AK lesions, each at least 4 mm in diameter on the face (excluding ears),
             forehead or bald scalp.

        Exclusion Criteria:

          1. Subject is pregnant, lactating, or is planning a pregnancy within the period of study
             participation.

          2. Subject suffers from excessive alcohol consumption, drug abuse or has a condition that
             could compromise the subject's ability to comply with study requirements.

          3. Presence of Atopic Dermatitis, Basal Cell Carcinoma, Eczema, Psoriasis, Rosacea,
             Squamous Cell Carcinoma or other possible confounding skin conditions on the
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Core Healthcare Group</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis ,AK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

